Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation.

Vassall, A; Siapka, M; Foster, N; Cunnama, L; Ramma, L; Fielding, K; McCarthy, K; Churchyard, G; Grant, A; Sinanovic, E; (2017) Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. The Lancet Global health, 5 (7). e710-e719. ISSN 2214-109X DOI: https://doi.org/10.1016/S2214-109X(17)30205-X

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S2214-109X(17)30205-X

Abstract

Share

Download

Filename: Cost-effectiveness of Xpert_GOLD VoR.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar